Drug intelligence / Profile preview

KCONVAC

Development stage: Phase 3
Lead developer: Shenzhen Kangtai Biological Products
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

KCONVAC is an inactivated COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd. The vaccine targets SARS-CoV-2 and is administered intramuscularly. It received emergency use authorization in China on May 14, 2021, becoming the fourth inactivated Chinese COVID-19 vaccine to be authorized for emergency use.

Brand names: KCONVAC可维克
Other names: Minhai COVID-19 vaccine康泰民海新冠疫苗

Beyond the preview

Go deeper on KCONVAC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KCONVAC.